Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11

Fig. 6

BMSCs-derived exosome miR-7-5p inhibits tumorigenicity of AML in vitro. A The identification of miR-7-5p expressing posterior to the transfection by qRT-PCR. B The identification of OSBPL11 mRNA expressing after transfection by qRT-PCR. C Exo-miR-7-5p mimics and Exo-miR-7-5p inhibitor were co-cultured with MOLM13 and HL-60 cells, respectively, and OSBPL11 protein expression after transfection was determined by Western blotting. D Representative images of colony formation of MOLM13 and HL-60 cells subjected to Exo-miR-7-5p mimics treatment or Exo-miR-7-5p inhibitor for 14 days, respectively. E Flow cytometry was employed to identify the programmed cell death of MOLM13 and HL-60 cells posterior to 24 h. Data are expressed as the average ± SD (n = 3). F Exo-miR-7-5p mimics or Exo-miR-7-5p inhibitor were co-cultured with MOLM13 and HL-60 cells for 24 h, protein expression of PI3K/AKT/mTOR signal path biomarkers were identified via immunoblotting. The quantitation data from immunoblotting analysis were analyzed via ImageJ program, which were expressed as average ± SD (n = 3). *p < 0.05 in contrast to the Exo-Nc-mimics, #p < 0.05 in contrast to the Exo-Nc-inhibitor

Back to article page